β-Cyclodextrin with terminal amino moiety(6-en-β-CD) was prepared by β-cyclodextrin(β-CD) as starting material through sulfonation and ethylenediamine substitution. Then, the target polymer[6-poly(glumatic acid-lysine)-β-CD] was obtained by ring opening polymerization(ROP) of glumatic acid and lysine N-carboxyl anhydride(NCA) and deprotection of benzoxycarbonyl(Cbz), with β-CD and polypeptides as its core and branched arms, respectively. The characters of the star-shaped polymer and its corresponding intermediates were determined by matrix-assisted laser desorption/ionization time of flight mass spectrometry(MALDI-TOF-MS), nuclear magnetic resonance(NMR) and Fourier transform infrared spectroscopy(FTIR), respectively. Moreover, the secondary structure and the cytotoxicity in vitro were also detected by circular dichroism(CD) and methylthiazolyldiphenyl-tetrazolium bromide(MTT) assay, respectively. The results showed that successful synthesis of the target polymer and its intermediates was achieved, and the molecular weight(Mw) of the target polymer, polydispersity index(PDI) and average degree of polymerization(DP) were 4626, 1.10 and 27.1, respectively. Furthermore, the secondary structure of the target polymer in water was random coil. The cell viability of human umbilical vein endothelial cells(HUVECs) could reach over 94% when the polymer concentration was up to 5 mg/mL, exhibiting no cell toxicity in vitro. In conclusion, our studies demonstrated that the polymer had potential applications in pharmacy industry.